Rallybio Q2 revenue falls, net loss narrows

Reuters
08/07
Rallybio <a href="https://laohu8.com/S/QTWO">Q2</a> revenue falls, net loss narrows

Overview

  • Rallybio Q2 revenue dips to $0.2 mln from $0.3 mln in 2024

  • Net loss narrows to $9.7 mln from $16.2 mln in Q2 2024

  • Co sells REV102 interest for up to $25 mln, extending cash runway

Outlook

  • Rallybio expects RLYB116 study data in 3Q and 4Q 2025

  • Company's cash runway extended into mid-2027 after REV102 sale

  • Rallybio anticipates complete complement inhibition in RLYB116 study

  • Company focuses RLYB116 on PTR and APS conditions

Result Drivers

  • REVENUE DECLINE - Decrease in revenue attributed to changes in collaboration agreements with Johnson & Johnson

  • R&D EXPENSES DROP - Lower R&D expenses due to decreased development costs for RLYB212 and other programs

  • CASH INFUSION - Sale of REV102 interest to Recursion Pharmaceuticals extends cash runway into mid-2027

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Net Income

-$9.70 mln

Q2 Basic EPS

-$0.22

Q2 Income From Operations

-$10.06 mln

Q2 Operating Expenses

$10.27 mln

Press Release: ID:nBw38yYrla

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10